A5088676113- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Urinary Bladder and Prostate Research
- Hormonal and reproductive studies
- MRI in cancer diagnosis
- AI in cancer detection
- Bladder and Urothelial Cancer Treatments
- Urologic and reproductive health conditions
- Health Systems, Economic Evaluations, Quality of Life
- Molecular Biology Techniques and Applications
- Urological Disorders and Treatments
- Medical Imaging Techniques and Applications
- Cancer Diagnosis and Treatment
- Reconstructive Surgery and Microvascular Techniques
- Artificial Intelligence in Healthcare
- Cancer-related molecular mechanisms research
- Radiation Therapy and Dosimetry
- Tannin, Tannase and Anticancer Activities
- Cancer, Lipids, and Metabolism
- Cardiac tumors and thrombi
- Ethics in Clinical Research
- Nutrition, Genetics, and Disease
- Hemodynamic Monitoring and Therapy
- Pharmacology and Obesity Treatment
Northwestern University
2024-2025
Objectives: To review outcomes for patients with irritable bowel syndrome (IBS) or inflammatory disease (IBD) who undergo holmium laser enucleation of prostate (HoLEP) bothersome urinary symptoms related to benign prostatic hyperplasia (BPH). Methods: We performed a retrospective had undergone HoLEP by single surgeon between January 2021 and August 2023. Preoperative, intraoperative, postoperative characteristics were compared an ICD-10 diagnosis IBS IBD those without, using Chi-square...
Abstract Checkpoint inhibitors targeting PD-1/PD-L1, such as pembrolizumab, can be effective in a small population of biomarker-selected patients with metastatic prostate cancer (mPC), has been demonstrated by case series. The objective this study is to help identify which are most likely benefit from pembrolizumab and estimate their likelihood response. This single-center we analyzed clinical data 18 mPC who were treated for biomarker-driven indication. We found that 38.9% showed 50% or...
36 Background: PET PSMA-based imaging for prostate cancer staging has been approved since late 2020 and was widely available in our medical system by July 2021. We sought to examine the patterns of use PSMA PET/CT conventional this time. Methods: retrospectively identified men who were diagnosed with presumptive NCCN unfavorable intermediate risk (UIR), high risk, or very (VHR) underwent work-up biochemical recurrence (BCR) from 2021 – June 2023. Patient clinical, pathological, variables...
Abstract Introduction The Society of Nuclear Medicine and Molecular Imaging (SNMMI) provides appropriate use criteria (AUC) for prostate‐specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) which include guidance on imaging in newly diagnosed prostate cancer patients with biochemically recurrent (BCR) disease. This study aims to examine trends PSMA implementation the prevalence outcomes scans ordered scenarios deemed rarely or not meeting SNMMI AUC....
To evaluate contemporary preoperative risk factors and subsequent postoperative management of incidental prostate cancer (iPCa) clinically significant (icsPCa, Grade Group [GG] ≥ 2 PCa).
338 Background: Active surveillance (AS) is the preferred management for men with NCCN very low or risk prostate cancer (PCa) and may be considered select favorable intermediate PCa. AS can associated significant grade reclassification progression to treatment, adverse pathology at radical prostatectomy (RP), need salvage therapy. Genomic transcriptomic biomarkers have been shown prognostic potentially predictive of treatment response in locally advanced metastatic setting. The potential...
274 Background: NCCN very low risk (VLR) prostate cancer is frequently clinically insignificant and thus over-diagnosed. Use of MRI prior to patient selection for biopsy inform targeting can reduce the diagnosis VLR disease. Indeed, a recent publication has reported no diagnoses since 2018. We sought better understand incidence disease in our multi-hospital institutional cohort. Methods: retrospectively identified 3197 patients who were newly diagnosed with at eleven-hospital system from...
297 Background: The very-low risk (VLR) substratification of prostate cancer has been called into question with the 2022 American Urological Association (AUA) guidelines dropping this designation. Historical data suggested men VLR disease have a reduced progression compared to other low (LR) men. In study, we evaluate contemporary initial management, progression, and predictors upgrading for LR patients in multi-centered hospital system. Methods: We retrospectively identified diagnosed or...
283 Background: PSMA-based imaging improves detection of metastatic disease for initial staging men diagnosed with prostate cancer (PCa) higher accuracy compared to conventional imaging. PSMA is now being increasingly adopted local and distant staging. We sought determine the contribution clinical pathological factors associated positive nodal or disease. Methods: retrospectively identified 404 PCa who underwent Gallium-68 F-18 piflufolastat (DCFPyL) PET/CT across our eleven-hospital system...
35 Background: PSMA PET is increasingly utilized for the evaluation of disease stage at biochemical recurrence. Here we evaluate association clinico-pathologic features with findings in biochemically recurrent patients after primary prostate radiation therapy (RT). Methods: We queried Northwestern Medical System Electronic Data Warehouse between July 2021 and March 2023 to identify 122 men treated RT presumptive localized cancer who subsequently underwent Gallium-68 or F-18 piflufolastat...